CervoMed Provides Update on Neflamapimod DLB Program as Part of Presentation at the 8th International Lewy Body Dementia Conference
Data from the first 16 weeks of the open-label extension phase of the RewinD-LB trial are expected in 1Q 2025 and will include data from participants who have received capsules from a more recently ma ...
CervoMed provides update on neflamapimod DLB program
CervoMed (CRVO) provided an update on its neflamapimod development program in dementia with Lewy bodies, DLB, as part of an oral presentation ...
News Medical on MSN17h
Alzheimer’s and Parkinson’s linked to aging brain’s failing waste disposal
New research uncovers how declining protein clearance mechanisms with age lead to Alzheimer’s, Parkinson’s, and other ...
manilatimes4h
SeaStar Medical Announces $6 Million Registered Direct Offering Priced At-the-Market
H.C. Wainwright & Co. is acting as the exclusive financial advisor to SeaStar Medical in connection with the offering.
Ozempic May Protect Against Alzheimer’s
One recent analysis found that, over the course of three years, people taking semaglutide (the compound in Ozempic and the weight loss drug Wegovy) were about 40 to 70 percent less likely to be ...